GB0722203D0 - Use of CRTH2 antagonist compounds - Google Patents

Use of CRTH2 antagonist compounds

Info

Publication number
GB0722203D0
GB0722203D0 GBGB0722203.7A GB0722203A GB0722203D0 GB 0722203 D0 GB0722203 D0 GB 0722203D0 GB 0722203 A GB0722203 A GB 0722203A GB 0722203 D0 GB0722203 D0 GB 0722203D0
Authority
GB
United Kingdom
Prior art keywords
antagonist compounds
crth2 antagonist
crth2
compounds
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0722203.7A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxagen Ltd
Original Assignee
Oxagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxagen Ltd filed Critical Oxagen Ltd
Priority to GBGB0722203.7A priority Critical patent/GB0722203D0/en
Publication of GB0722203D0 publication Critical patent/GB0722203D0/en
Priority to DE08851028T priority patent/DE08851028T1/de
Priority to EP08851028A priority patent/EP2219645A2/fr
Priority to ES08851028T priority patent/ES2353055T1/es
Priority to PCT/GB2008/003824 priority patent/WO2009063202A2/fr
Priority to JP2010532660A priority patent/JP2011503045A/ja
Priority to US12/779,638 priority patent/US20110124683A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
GBGB0722203.7A 2007-11-13 2007-11-13 Use of CRTH2 antagonist compounds Ceased GB0722203D0 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
GBGB0722203.7A GB0722203D0 (en) 2007-11-13 2007-11-13 Use of CRTH2 antagonist compounds
DE08851028T DE08851028T1 (de) 2007-11-13 2008-11-13 Verwendung von crth2-antagonisten-verbindungen
EP08851028A EP2219645A2 (fr) 2007-11-13 2008-11-13 Utilisation de composés antagonistes de crth2
ES08851028T ES2353055T1 (es) 2007-11-13 2008-11-13 Uso de compuestos antagonistas de crth2.
PCT/GB2008/003824 WO2009063202A2 (fr) 2007-11-13 2008-11-13 Utilisation de composés antagonistes de crth2
JP2010532660A JP2011503045A (ja) 2007-11-13 2008-11-13 Ｃｒｔｈ２拮抗化合物の使用
US12/779,638 US20110124683A1 (en) 2007-11-13 2010-05-13 Use of CRTH2 Antagonist Compounds

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0722203.7A GB0722203D0 (en) 2007-11-13 2007-11-13 Use of CRTH2 antagonist compounds

Publications (1)

Publication Number Publication Date
GB0722203D0 true GB0722203D0 (en) 2007-12-19

Family

ID=38858584

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0722203.7A Ceased GB0722203D0 (en) 2007-11-13 2007-11-13 Use of CRTH2 antagonist compounds

Country Status (6)

Country Link
EP (1) EP2219645A2 (fr)
JP (1) JP2011503045A (fr)
DE (1) DE08851028T1 (fr)
ES (1) ES2353055T1 (fr)
GB (1) GB0722203D0 (fr)
WO (1) WO2009063202A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602008005796D1 (de) * 2007-12-14 2011-05-05 Pulmagen Therapeutics Asthma Ltd Indole und ihre therapeutische verwendung
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
NZ587251A (en) * 2008-01-18 2011-12-22 Oxagen Ltd Indole derivatives having CRTH2 antagonist activity
EP2265581A1 (fr) * 2008-01-22 2010-12-29 Oxagen Limited Composés présentant une activité antagoniste du récepteur crth2
JP2011509991A (ja) * 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
KR101235961B1 (ko) 2008-02-01 2013-02-21 판미라 파마슈티칼스, 엘엘씨 프로스타글란딘 ｄ２ 수용체의 ｎ,ｎ-이치환 아미노알킬비페닐 길항제
EP2257536A4 (fr) 2008-02-14 2011-03-23 Amira Pharmaceuticals Inc Composés diaryliques cycliques en tant qu'antagonistes de récepteurs de prostaglandine d2
US8426449B2 (en) 2008-04-02 2013-04-23 Panmira Pharmaceuticals, Llc Aminoalkylphenyl antagonists of prostaglandin D2 receptors
US8501959B2 (en) 2008-06-24 2013-08-06 Panmira Pharmaceuticals, Llc Cycloalkane[B]indole antagonists of prostaglandin D2 receptors
US20110144160A1 (en) 2008-07-03 2011-06-16 Amira Pharmaceuticals, Inc. Antagonists of Prostaglandin D2 Receptors
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
GB2465062B (en) 2008-11-06 2011-04-13 Amira Pharmaceuticals Inc Cycloalkane(B)azaindole antagonists of prostaglandin D2 receptors
WO2010057118A2 (fr) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
KR20120038544A (ko) 2009-07-31 2012-04-23 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 수용체 길항제의 안과용 약학 조성물
MX2012001542A (es) 2009-08-05 2012-06-19 Panmira Pharmaceuticals Llc Antagonista dp2 y usos del mismo.
US9688624B2 (en) 2010-01-06 2017-06-27 Brickell Biotech, Inc. DP2 antagonist and uses thereof
CN102791689B (zh) 2010-03-22 2014-10-29 埃科特莱茵药品有限公司 3-（杂芳基-氨基）-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途
JP5952829B2 (ja) * 2010-12-23 2016-07-13 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｃｒｔｈ２受容体調節剤としてのキノキサリン類およびアザ−キノキサリン類
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
LT2697223T (lt) 2011-04-14 2016-10-10 Actelion Pharmaceuticals Ltd. 7-(heteroaril-amino)-6,7,8,9-tetrahidropirido[1,2-a]indolacto rūgšties dariniai ir jų, kaip prostaglandino d2 receptoriaus moduliatorių, panaudojimas
CN103086943B (zh) * 2011-11-04 2015-04-15 山东亨利医药科技有限责任公司 作为crth2受体拮抗剂的吲哚类衍生物
PE20161177A1 (es) 2014-03-17 2016-11-18 Actelion Pharmaceuticals Ltd Derivados del acido acetico azaindol y su uso como moduladores del receptor de prostaglandina d2
BR112016021443A8 (pt) 2014-03-18 2017-12-26 Actelion Pharmaceuticals Ltd Derivados de ácido acético azaindol e seu uso como moduladores de receptor de prostaglandina d2
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
ES2867757T3 (es) 2015-09-15 2021-10-20 Idorsia Pharmaceuticals Ltd Formas cristalinas
JPWO2017104728A1 (ja) * 2015-12-16 2018-11-29 幸久 村田 食物アレルギー治療薬
AU2017298256B2 (en) * 2016-07-21 2020-11-26 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Indole derivative used as CRTH2 inhibitor

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0324763D0 (en) * 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0504150D0 (en) * 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) * 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
GB0605743D0 (en) * 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
DK2046740T3 (da) * 2006-07-22 2012-08-20 Oxagen Ltd Forbindelser med CRTH2-antagonistisk virkning

Also Published As

Publication number Publication date
ES2353055T1 (es) 2011-02-25
WO2009063202A3 (fr) 2009-08-27
WO2009063202A2 (fr) 2009-05-22
EP2219645A2 (fr) 2010-08-25
JP2011503045A (ja) 2011-01-27
DE08851028T1 (de) 2011-02-24

Similar Documents

Publication Publication Date Title
GB0722216D0 (en) Use of crth2 antagonist compounds
GB0722203D0 (en) Use of CRTH2 antagonist compounds
HK1145175A1 (en) Compounds having crth2 antagonist activity
IL196640A0 (en) Compounds having crth2 antagonist activity
HK1172326A1 (en) Compounds and compositions and methods of use
HK1147674A1 (en) Heterocyclic compounds as crth2 receptor antagonists crth2
IL202679A0 (en) Particulates of a crth2 antagonist
AP2008004406A0 (en) Methods of managing timberland
PL2328545T3 (pl) Zastosowanie glukozyloglicerolu
HK1160925A1 (zh) 組織蛋白酶 的用途
AP2784A (en) Methods of managing timberland
HK1137187A1 (en) Use of tocopherol
ZA200806508B (en) Salt of CD80 Antagonist
ZA200900393B (en) Compounds having CRTH2 antagonist activity
PL2237782T3 (pl) Zastosowanie tetrahydropirymidyn
GB0801674D0 (en) Compounds having CRTH2 antagonist activity
GB201114396D0 (en) Location of basesation
GB0800874D0 (en) Compounds having CRTH2 antagonist activity
GB0801132D0 (en) Compounds having CRTH2 antagonist activity
GB0820526D0 (en) Compounds having crth2 antagonist activity
GB0801671D0 (en) Compounds having crth2 antagonist activity
GB0801672D0 (en) Compounds having crth2 antagonist activity
GB0801131D0 (en) Compounds having CRTH2 antagonist activity
GB0624176D0 (en) Compounds having CRTH2 antagonist activity
PL383760A1 (pl) Nowe zastosowanie undekan-2-olu

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)